#specialty medicines

2 stories

#oncology #saroglitazar #zydus lifesciences #biologics #car-t therapy #complex biologics #ebitda #glp-1 #us generics #us launch

Zydus Lifesciences Growth Strategy
Zydus forecasts steady growth for five years as innovation matures.
The Economic Times · 1m
Zydus Targets New Growth Areas
Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics.
The Economic Times · 1m